All Stories

  1. Association between Corrected QT Interval and C-Reactive Protein in Patients with Inflammatory Bowel Diseases
  2. Could Pirfenidone Also be Effective in Treating Intestinal Fibrosis?
  3. Persistent Iron Deficiency Anemia in Patients with Celiac Disease Despite a Gluten-Free Diet
  4. Non-medical Switching of Infliximab to CT-P13 Biosimilar in Inflammatory Bowel Disease: A Focus on the Definition of “Non-medical Switch”
  5. Topography, morphology, and etiology of lymphocytic gastritis: a focus on celiac disease
  6. Food Allergy Insights: A Changing Landscape
  7. Celiac Disease, Gluten-Free Diet, and Metabolic and Liver Disorders
  8. Controversial Contribution of Th17/IL-17 Toward the Immune Response in Intestinal Fibrosis
  9. Is fecal calprotectin an accurate marker in the management of Crohn's disease?
  10. Topical Aminosalicylates and Histologic Healing in Ulcerative Colitis
  11. Food Allergies and Ageing
  12. Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus
  13. Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?
  14. Wegener’s granulomatosis and retroperitoneal fibrosis: a case report and review of the literature
  15. Duodenal lymphocytosis in functional dyspepsia
  16. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
  17. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
  18. Metabolic Alterations in Celiac Disease Occurring after Following a Gluten-Free Diet
  19. Mesalazine treatment in organotypic culture of celiac patients: Comparative study with gluten free diet
  20. The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine
  21. Mastocytic enterocolitis: Increase of mast cells in the gastrointestinal tract of patients with chronic diarrhea
  22. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
  23. Subtypes of chronic gastritis in patients with celiac disease before and after gluten-free diet
  24. Effects of Exercise Training on Delaying Disease Progression in Patients with Chronic Kidney Disease: a Review of the Literature
  25. Non-Celiac Gluten Sensitivity among Patients Perceiving Gluten-Related Symptoms
  26. Nanotechnology in the treatment of inflammatory bowel diseases
  27. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy
  28. Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis
  29. Mesalazine vanishing time from rectal mucosa following its topical administration
  30. Clinical course of Crohn’s disease first diagnosed at surgery for acute abdomen
  31. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFα therapy
  32. Safe use of infliximab for the treatment of fistulizing Crohnʼs disease during pregnancy within 3 months of conception
  33. Early versus late surgery for ileo-caecal Crohn’s disease
  34. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases
  35. Another paradox in Crohnʼs disease: New onset of psoriasis in a patient receiving tumor necrosis factor-α antagonist
  36. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up
  37. Current management of severe ulcerative colitis
  38. Mucosal features and granulocyte–monocyte-apheresis in steroid-dependent/refractory ulcerative colitis
  39. Seasonal variations in onset of symptoms in Crohn's disease
  40. Ferritin as a simple indicator of iron deficiency in anemic IBD patients
  41. MR Imaging in Patients with Crohn Disease: Value of T2- versus T1-weighted Gadolinium-enhanced MR Sequences with Use of an Oral Superparamagnetic Contrast Agent
  42. Increased risk of breast cancer in first-degree relatives of Crohn's disease patientsAn IG-IBD study
  43. Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study
  44. Two synchronous adenocarcinomas of the small bowel in a patient with undiagnosed Crohn's disease of the terminal ileum
  45. Inflammatory bowel diseases: clinical update of practical guidelines
  46. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement
  47. A New Oral Delivery System for 5-ASA: Preliminary Clinical Findings for MMX
  48. Small Intestine Contrast Ultrasonography
  49. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations
  50. Efficacy of conventional immunosuppressive drugs in IBD
  51. Development of Fistulae in Ileo-Anal Pouch does not Necessarily Indicate Crohn's Disease
  52. Infliximab and quality of life in steroid-dependent Crohn’s disease
  53. An unusual treatment for a colonic polyp
  54. Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence
  55. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis
  56. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial
  57. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon
  58. Biological agents in the treatment of Crohn's disease
  59. MRI evaluation of Crohn's disease of the small and large bowel with the use of negative superparamagnetic oral contrast agents
  60. Survival and causes of death in Italian patients with ulcerative colitis A GISC nation-wide study
  61. Evaluation of Crohn disease activity with magnetic resonance imaging
  62. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment
  63. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC)
  64. Prognostic factors for postoperative recurrence of Crohnʼs disease